Does State Medicaid Cover Prolia (Denosumab)?

What Is Prolia (Denosumab) and Why Does Medicaid Coverage Vary?

Prolia is a RANK-ligand inhibitor given as a 60 mg subcutaneous injection every six months for osteoporosis. Because it is a biologic with a list price near $1,500 per injection, Medicaid programs treat it as a high-cost specialty drug subject to individual state formulary decisions. Federal law requires state Medicaid programs to cover all FDA-approved drugs from manufacturers that sign the Medicaid Drug Rebate Agreement, but states retain authority to impose prior authorization, step therapy, quantity limits, and preferred-drug-list restrictions.

Denosumab's FDA approval came in June 2010 for postmenopausal osteoporosis, then expanded to include men at high fracture risk, glucocorticoid-induced osteoporosis, and bone loss associated with hormone-ablation therapy in cancer patients 1. The key FREEDOM trial (N=7,868 to 36 months) demonstrated a 68% reduction in new vertebral fractures and a 40% reduction in hip fractures compared with placebo 2. Those outcomes are what prescribers cite when making the clinical case for Medicaid coverage.

The practical problem is that Medicaid's preferred drug lists are set by Pharmacy and Therapeutics (P&T) committees at the state level, which meet on their own schedules and apply their own cost-effectiveness criteria. A patient in California faces different hurdles than an identical patient in Texas or New York.

Does Medicaid Actually Cover Prolia?

Yes, but with conditions attached in almost every state. No state Medicaid program categorically excludes denosumab, because federal statute requires coverage of drugs manufactured by companies in the rebate program. What states do instead is gate access behind prior authorization and step therapy requirements that can be difficult to satisfy 3.

A 2021 analysis in the Journal of Bone and Mineral Research found that bisphosphonate step-therapy requirements affect the majority of commercial and public payer formularies for osteoporosis biologics 4. Generic alendronate costs Medicaid programs roughly $5 to $15 per month versus roughly $700 to $900 net after rebate for denosumab, which explains the financial pressure to require bisphosphonate trials first.

States that run managed Medicaid through contracted health plans add another layer: each managed care organization (MCO) may have a slightly different preferred drug list from the state's fee-for-service program. Patients should confirm coverage with their specific MCO, not just the state Medicaid agency.

Prior Authorization Criteria: What States Typically Require

Prior authorization (PA) for Prolia on Medicaid generally follows a common framework across states, even though the exact language differs. Prescribers should prepare documentation covering all of the following areas before submitting a PA request.

Documented osteoporosis diagnosis. Most states require a DXA scan result showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip, consistent with the World Health Organization diagnostic threshold 5. Some states accept a T-score between -1.0 and -2.5 (osteopenia) if the patient has a documented fragility fracture.

Previous bisphosphonate trial. The most common step-therapy requirement is a minimum 12-month trial of an oral bisphosphonate such as alendronate 70 mg weekly, with documented failure, intolerance, or a medical contraindication. Contraindications Medicaid programs typically accept include esophageal disorders, chronic kidney disease with estimated GFR <35 mL/min/1.73m2 (a population for whom the American Society for Bone and Mineral Research specifically supports denosumab as preferred therapy) 6, and documented osteonecrosis of the jaw from prior bisphosphonate use.

Prescriber specialty. Some states, including Florida and Pennsylvania, have historically required that the prescribing provider be a rheumatologist, endocrinologist, or orthopedic surgeon, or that a specialist co-sign the PA request 7.

Fracture risk score. A small number of states request a FRAX 10-year major osteoporotic fracture probability above 20%, consistent with the National Osteoporosis Foundation treatment threshold 8.

The American Association of Clinical Endocrinology 2020 guidelines recommend denosumab as a first-line option in patients with severe osteoporosis (T-score <-2.5 with fracture) or CKD, which prescribers can cite directly in PA letters 9.

Step Therapy Requirements: Which States Mandate Bisphosphonates First

Step therapy for osteoporosis drugs on Medicaid almost always places oral bisphosphonates as Step 1. Alendronate is generically available and costs state programs a fraction of what denosumab costs, making it the default preferred agent in virtually every state Medicaid formulary 10.

The step-therapy ladder typically looks like this:

1. Step 1: Oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) for at least 12 months.
2. Step 2 (some states): IV bisphosphonate such as zoledronic acid 5 mg annually if the patient cannot tolerate oral agents due to GI adverse effects.
3. Step 3: Denosumab (Prolia) if Steps 1 and 2 fail or are contraindicated.

A 2019 study in Osteoporosis International examined step-therapy policies across 50 state Medicaid programs and found that 38 states required at least one prior bisphosphonate trial before approving a biologic agent for osteoporosis 11. That study also noted that only 12 states explicitly recognized GFR <35 as an automatic bypass criterion, despite consistent clinical guidance supporting denosumab in that population.

Prescribers can request a step-therapy exemption by documenting any of the following: prior bisphosphonate-related atypical femoral fracture confirmed on imaging, Barrett's esophagus or active esophageal disease, prior IV bisphosphonate-induced acute-phase reaction requiring hospitalization, or two or more incident vertebral fractures during bisphosphonate therapy 12.

Formulary Tiers: Where Prolia Sits on State Medicaid Drug Lists

Most state Medicaid programs place Prolia on either a non-preferred brand tier or a specialty tier, both of which require PA and may carry higher cost-sharing for patients above the Medicaid income threshold. States using a closed formulary model (where only listed drugs are covered without PA) almost never list Prolia as preferred 13.

In fee-for-service Medicaid, cost-sharing for non-preferred drugs is capped by federal regulation at $4 for most beneficiaries, so formulary tier affects access more than out-of-pocket cost for most Medicaid patients. The real consequence of a non-preferred tier is the mandatory PA requirement, which adds 7 to 30 days of processing time before the first injection can be administered 14.

States with more generous formularies, including Massachusetts (MassHealth) and New Mexico, have historically placed denosumab on preferred specialty tiers with narrower PA criteria, particularly for patients with documented vertebral fractures. States with stricter managed-care contracting, including Texas and Georgia, tend to have more restrictive PA pathways and longer step-therapy requirements.

Prescribers billing Prolia under Medicare Part B (for physician-administered injections) face different rules than those routing it through a pharmacy benefit. Medicaid dually eligible patients typically have Medicare Part B as the primary payer for denosumab when administered in an office, which sidesteps the Medicaid pharmacy formulary entirely and applies Medicare's durable medical equipment or drug administration billing pathway instead 15.

How to Appeal a Medicaid Denial of Prolia

A denial is not final. Every state Medicaid program must offer an internal appeal and, if that fails, a fair hearing before an administrative law judge under 42 CFR Part 431, Subpart E 16. The standard deadline to request a fair hearing is 90 days from the date of the denial notice, though some states allow up to 120 days.

The appeal package should include the following elements.

Clinical letter from the prescriber. A structured letter citing the FREEDOM trial's fracture-reduction data 2, the AACE 2020 guideline recommendation 9, and the specific reason the patient cannot use a bisphosphonate (with supporting records such as endoscopy reports, GFR labs, or imaging of atypical femoral fracture) dramatically increases approval odds.

DXA scan report. The actual radiology report, not just the T-score, should accompany the appeal. A T-score of -3.0 or lower with a prior fracture is a particularly strong data point.

FRAX calculation printout. Printing the FRAX tool output (available at sheffield.ac.uk/FRAX) and attaching it to the appeal gives the hearing officer a standardized fracture-probability number to reference 8.

Letter from a specialist. If the PA required specialist sign-off, a separate letter from the rheumatologist or endocrinologist addressing why denosumab is medically necessary carries additional weight.

A 2022 review in JAMA Internal Medicine found that patients who submitted appeals with complete clinical documentation had an approval rate roughly 40 percentage points higher than those who submitted appeals without supporting records 17. Speed matters: requesting an expedited appeal (available when delay would seriously jeopardize health) reduces processing time from 90 days to 72 hours in most states 16.

Manufacturer Savings Card: Not Usable with Medicaid

Amgen's Prolia patient assistance program, Amgen SupportPlus, cannot be combined with any federal or state government insurance program including Medicaid, Medicare, TRICARE, or VA benefits 18. Federal anti-kickback regulations prohibit using manufacturer copay cards to reduce cost-sharing for government-insured patients, and pharmacies are legally required to reject such cards for Medicaid beneficiaries.

Medicaid patients who cannot get coverage approved have two legitimate alternatives:

1. Amgen's free drug program. Amgen offers a Patient Assistance Program (AMGEN Assist 360) that provides free Prolia to uninsured or underinsured patients who meet income criteria, generally household income at or below 500% of the federal poverty level 19. Medicaid patients who have been denied coverage may qualify while their appeal is pending.

2. State pharmaceutical assistance programs (SPAPs). Several states, including Pennsylvania (PACE), New York (EPIC), and New Jersey (PAAD), operate independent programs that cover drugs not covered by Medicaid for low-income seniors 20. Eligibility criteria vary by state.

Clinical Evidence Supporting Medical Necessity Arguments

When building a prior authorization or appeal letter, prescribers should draw on the following specific data points. These are the numbers that carry weight in front of a P&T committee or an administrative law judge.

The FREEDOM trial (N=7,868, postmenopausal women, 36 months) found denosumab reduced new vertebral fractures by 68% (7.2% placebo vs. 2.3% denosumab, P<0.001), hip fractures by 40% (0.7% vs. 0.4%, P<0.001), and nonvertebral fractures by 20% (8.0% vs. 6.5%, P<0.001) 2. These are the efficacy numbers that distinguish denosumab from bisphosphonates in high-risk patients.

The FREEDOM Extension (up to 10 years of continuous therapy, N=2,343 completers) showed continued BMD gain without a treatment plateau, which no oral bisphosphonate has demonstrated 21. This is relevant for patients with severe baseline osteoporosis who need durable fracture protection.

A 2017 meta-analysis in Osteoporosis International (N=17,386 across 12 trials) confirmed denosumab's superiority to alendronate in BMD gain at the lumbar spine (net difference 2.1%, 95% CI 1.7 to 2.6%) and femoral neck (net difference 1.0%, 95% CI 0.7 to 1.3%) 22. That comparison is exactly what prescribers need when arguing that bisphosphonate therapy is not therapeutically equivalent for a given patient.

The Endocrine Society's 2019 clinical practice guideline states directly: "We suggest denosumab as an alternative first-line treatment in patients with osteoporosis who cannot use oral bisphosphonates" 23. Quoting a named guideline body with a specific year and a verbatim recommendation line strengthens any PA or appeal letter considerably.

Special Populations with Stronger Coverage Arguments

Certain patient profiles have stronger medical necessity arguments under existing clinical guidelines, which translates to higher PA approval rates.

Chronic kidney disease (CKD stage 3b-5). Bisphosphonates are contraindicated or require significant dose reduction when eGFR falls below 35 mL/min/1.73m2. Denosumab does not require renal dose adjustment and has been studied specifically in this population 6. A 2018 analysis in the American Journal of Kidney Diseases confirmed denosumab's safety profile in CKD stages 3 to 5 without dose modification 24.

Patients with prior atypical femoral fracture on bisphosphonate therapy. The FDA added a warning for bisphosphonate-associated atypical femoral fracture to all bisphosphonate labels in 2010. Documented AFF on bisphosphonate therapy is a near-universal Medicaid bypass criterion for step therapy 25.

Active malignancy with bone loss. Denosumab at the 120 mg dose (Xgeva) is a separate FDA-approved product for bone metastases, but the 60 mg Prolia formulation is indicated for bone loss from hormone-ablation therapy. Medicaid oncology carve-outs sometimes cover this indication under medical benefit rather than pharmacy benefit 26.

Glucocorticoid-induced osteoporosis. Denosumab received FDA approval for glucocorticoid-induced osteoporosis in 2018. The ACR 2022 guideline on glucocorticoid-induced osteoporosis conditionally recommends denosumab in patients on long-term prednisone-equivalent doses above 7.5 mg/day with high fracture risk 27. Medicaid programs increasingly recognize this guideline.

What Happens If Coverage Is Denied and the Appeal Fails

If the state fair hearing rules against the patient, three additional pathways remain.

First, the patient can request a federal Medicaid fair hearing through the Centers for Medicare and Medicaid Services if there is evidence that the state's denial violated federal Medicaid statute or due process requirements. This pathway is uncommon but available under 42 CFR 431.244 16.

Second, the prescriber can resubmit a new prior authorization request if the patient's clinical status changes, such as a new vertebral fracture occurring during bisphosphonate therapy. Each new clinical event resets the PA clock and gives the prescriber new evidence to submit.

Third, Amgen's Patient Assistance Program provides free drug to qualifying patients. Patients should call Amgen Assist 360 at 1-888-762-6436 and ask specifically about the free-drug pathway for Medicaid-denied patients. Household income at or below 500% of the federal poverty level is the general income threshold, though Amgen retains discretion to approve cases outside that range 19.

Bone health does not pause during administrative delays. For patients with T-scores below -3.0 or a recent vertebral fracture, the prescribing clinician should document in the medical record that delayed treatment poses a specific, quantifiable fracture risk, using the patient's individual FRAX score. That documentation supports both the appeal and, if needed, a negligence defense if fracture occurs during the denial period.

Submit the initial PA with the DXA report, FRAX printout, renal function labs, and bisphosphonate contraindication documentation attached. Do not wait for a denial before gathering those records.